Classifications: angiotensin-converting enzyme (ace) inhibitor; antihypertensive agent; Therapeutic: antihypertensive agent; ace inhibitor
Pregnancy Category: C first trimester; D second and third trimester
2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg tablets
Lowers BP by specific inhibition of the angiotensin-converting enzyme (ACE). This interrupts conversion sequences initiated
by renin that form angiotensin II, a potent vasoconstrictor. ACE inhibition alters hemodynamics without compensatory reflex
tachycardia or changes in cardiac output (except in patients with CHF).
Improved cardiac output and exercise tolerance due to inhibition of ACE also decreases circulating aldosterone, which is
normally released in response to angiotensin II stimulation. Reduced aldosterone is associated with a potassium-sparing effect.
Also decreases peripheral resistance (afterload) and pulmonary vascular resistance.
Hypertension, alone or concomitantly with other classes of antihypertensive agents; CHF; to improve MI survival.
Patients with a history of angioedema related to treatment with an ACE inhibitor, ACE inhibitor hypersensitivity; pregnancy
(C first trimester, category D second and third trimester), children <6 y; lactation.
Impaired kidney function, renal artery stenosis, renal disease, renal failure, hyperkalemia, patients on diuretic therapy;
aortic stenosis, cardiomyopathy; cerebrovascular disease; collagen vascular disease; coronary artery disease, dialysis; older
adults; heart failure, hyperkalemia, hypotension, hypovolemia; African Americans; autoimmune diseases, especially systemic
lupus erythematosus (SLE).
Route & Dosage
Adult: PO 10 mg once/d, may increase up to 2040 mg 12 times/d (max: 80 mg/d)
Child (616 y): PO Start at 0.07 mg/kg (max 5 mg) once/d (max: 40 mg/d)
Geriatric: PO Initial 2.55 mg/d, may increase by 2.55 mg/d every 12 wk (max: 40 mg/d)
Adult: PO 540 mg/d
- Give an initial dose of 5 mg for diuretic-treated patients. Monitor drug effect for 2 h or until the BP is stabilized for
at least 1 additional hour. Concurrent administration with a diuretic may compound hypotensive effect.
- Give before dialysis; lisinopril is removed from blood by hemodialysis.
- Store away from both moisture and heat.
Adverse Effects (≥1%)CNS:
Headache, dizziness, fatigue
Hypotension, chest pain. GI:
Nausea, vomiting, diarrhea, anorexia, constipation
, intestinal angioedema. Hematologic:
Dyspnea, cough. Skin:
Azotemia, hyperkalemia, increased BUN, and creatinine levels.
and other nsaid
s may decrease antihypertensive activity; potassium supplements
, potassium-sparing diuretics
may cause hyperkalemia; may increase lithium
levels and toxicity.
25% absorbed from GI tract. Onset:
1 h. Peak:
68 h. Duration:
24 h. Distribution:
Limited amount crosses bloodbrain barrier; crosses placenta; small amount distributed in breast milk. Metabolism:
Is not metabolized. Elimination:
Primarily in urine. Half-Life:
Assessment & Drug Effects
- Place patient in supine position and notify physician if sudden and severe hypotension occurs within the first 15
h after initial drug dose; possible particularly in patients who are sodium- or volume-depleted because of diuretic therapy.
- Measure BP just prior to dosing to determine whether satisfactory control is being maintained for 24 h. If the antihypertensive
effect is diminished in less than 24 h, an increase in dosage may be necessary.
- Monitor closely for angioedema of extremities, face, lips, tongue, glottis, and larynx. Discontinue drug promptly and notify
physician if such symptoms appear; carefully monitor for airway obstruction until swelling is relieved.
- Monitor serum sodium and serum potassium levels for hyponatremia and hyperkalemia.
- Lab tests: Determine WBC count prior to initiation of treatment, every month for the first 36 mo of therapy, and at
periodic intervals for 1 y. Withhold therapy and notify physician if neutropenia (neutrophil count <1000/mm3) develops; kidney function tests at periodic intervals, especially in patients with severe volume or sodium replacement
or those with severe CHF.
Patient & Family Education
- Discontinue drug and contact physician immediately for severe hypersensitivity reaction (e.g., hoarseness, swelling of the
face, mouth, hands, or feet, or sudden trouble breathing).
- Be aware of importance of proper diet, including sodium and potassium restrictions. Do NOT use salt substitute containing
- Continued compliance with high BP medication is very important. If a dose is missed, take it as soon as possible but not
too close to next dose.
- Do not drive or engage in other potentially hazardous activities until response to the drug is known.
- With concomitant therapy, lisinopril increases the risk of lithium toxicity.
- Notify physician promptly of any indication of infection (e.g., sore throat, fever).
- Do not store drug in a moist area. Heat and moisture may cause the medicine to break down.